Jpmorgan Chase & CO Spruce Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 71 shares of SPRB stock, worth $25. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71
Previous 72
1.39%
Holding current value
$25
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SPRB
# of Institutions
34Shares Held
15.4MCall Options Held
16.7KPut Options Held
1.1K-
River Vest Venture Management LLC St. Louis, MO2.94MShares$1.06 Million20.39% of portfolio
-
Carlyle Group Inc. Washington, DC2.9MShares$1.04 Million0.2% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.61MShares$939,2850.04% of portfolio
-
Abingworth LLP London, X01.79MShares$645,3060.65% of portfolio
-
Acadian Asset Management LLC Boston, MA1.26MShares$453,2940.0% of portfolio
About SPRUCE BIOSCIENCES, INC.
- Ticker SPRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,560,200
- Market Cap $8.48M
- Description
- Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...